
Modafinil
Modafinil (Provigil and generics) is a Schedule IV prescription tablet that reduces excessive daytime sleepiness in adults with narcolepsy, obstructive sleep apnea and shift work disorder. In randomized trials it kept people awake longer on objective tests and improved how sleepy they felt, though many still had some sleepiness. In healthy, rested adults its effect on thinking is small. Rare but serious skin and allergic reactions, psychiatric symptoms and reduced effectiveness of hormonal birth control are the key cautions.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with diagnosed narcolepsy, obstructive sleep apnea with ongoing sleepiness despite airway treatment, or shift work disorder, prescribed and monitored by a doctor
Common dosing range
Set by your prescriber. Label dose: 200 mg once a day in the morning for narcolepsy or OSA; 200 mg about 1 hour before the work shift for shift work disorder; half the dose in severe liver impairment; consider lower doses in older adults
When to expect effects
Blood levels peak 2 to 4 hours after a dose; trial benefits were measured over 4 to 12 weeks
Watch out for
No boxed warning. The label tells patients to stop it and contact their doctor right away at the first sign of rash, hives, mouth sores, blisters, swelling or trouble swallowing or breathing (serious rash including Stevens-Johnson syndrome, and multi-organ allergic reactions). It can cause anxiety, mania or psychosis, more patients on it needed new or higher blood pressure medicine, and hormonal birth control may fail during use and for one month after. Schedule IV controlled substance
What is it
Modafinil is an FDA-approved prescription medicine that promotes wakefulness, sold as Provigil and as generic 100 mg and 200 mg tablets. Its current label approves it for one purpose: to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea (OSA) or shift work disorder. In OSA it treats the sleepiness, not the blocked airway, so CPAP or other airway treatment continues. In the US it is a Schedule IV controlled substance, it is not approved for children, and the European Medicines Agency removed its OSA indication in 2011. Modafinil is a mixture of two mirror-image forms; armodafinil is its R-form. People also use it off-prescription as a "smart drug" to boost focus, which is not an approved use.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
excessive daytime sleepiness in narcolepsy Good Evidence | Significant improvement in objective and self-rated sleepiness over 9 weeks; similar to sodium oxybate and pitolisant | Adults with narcolepsy whose main problem is daytime sleepiness | Measured over 9 weeks |
residual sleepiness in obstructive sleep apnea despite CPAP Good Evidence | Epworth score about 2.2 points better and wakefulness test about 3 minutes longer than placebo | Adults with OSA who use CPAP or other airway treatment and remain sleepy | Measured at about 4 weeks |
excessive sleepiness in shift work disorder Good Evidence | Clinical improvement in 74% versus 36% on placebo | People with diagnosed chronic shift work disorder | Measured monthly over 3 months |
thinking skills in healthy, rested adults ("smart drug" use, off-label) Limited Evidence | Overall SMD 0.12 on cognitive tests (small) | None established | Hours after a single dose in lab studies |
excessive daytime sleepiness in narcolepsy
- Effect
- Significant improvement in objective and self-rated sleepiness over 9 weeks; similar to sodium oxybate and pitolisant
- Best fit
- Adults with narcolepsy whose main problem is daytime sleepiness
- Time
- Measured over 9 weeks
residual sleepiness in obstructive sleep apnea despite CPAP
- Effect
- Epworth score about 2.2 points better and wakefulness test about 3 minutes longer than placebo
- Best fit
- Adults with OSA who use CPAP or other airway treatment and remain sleepy
- Time
- Measured at about 4 weeks
excessive sleepiness in shift work disorder
- Effect
- Clinical improvement in 74% versus 36% on placebo
- Best fit
- People with diagnosed chronic shift work disorder
- Time
- Measured monthly over 3 months
thinking skills in healthy, rested adults ("smart drug" use, off-label)
- Effect
- Overall SMD 0.12 on cognitive tests (small)
- Best fit
- None established
- Time
- Hours after a single dose in lab studies
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
excessive daytime sleepiness in narcolepsy
Disease adjunctTwo US 9-week double-blind trials randomized people with narcolepsy to modafinil 200 mg, 400 mg or placebo daily (283 people at 18 centers, and 271 people at 21 centers). Modafinil significantly improved objective sleepiness on the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test, self-rated sleepiness on the Epworth Sleepiness Scale, and clinician-rated illness; nighttime sleep was not harmed. When treatment was stopped in the second trial, sleepiness returned to baseline without amphetamine-like withdrawal. A network meta-analysis of 14 randomized trials found modafinil 200 to 400 mg had efficacy on sleepiness similar to sodium oxybate 9 g and pitolisant up to 40 mg, but only the latter two showed a benefit on cataplexy. A 2022 network meta-analysis of 19 trials (2,504 patients) found solriamfetol better than modafinil on the wakefulness test (SMD 0.42, 95% CI 0.05 to 0.79). The placebo-controlled trials lasted 9 weeks.
Bottom line: Modafinil reliably reduces daytime sleepiness in narcolepsy, with effects that fade when it is stopped.
residual sleepiness in obstructive sleep apnea despite CPAP
Disease adjunctA meta-analysis of 10 randomized placebo-controlled trials (1,466 adults with OSA still sleepy despite CPAP) found modafinil or armodafinil improved the Epworth Sleepiness Scale by 2.2 points (95% CI 1.5 to 2.9) and the Maintenance of Wakefulness Test by 3 minutes (95% CI 2.1 to 3.8). They tripled adverse events and doubled withdrawals because of adverse events, but did not increase serious adverse events. A 2023 network meta-analysis of 14 trials (3,085 patients) rated the 4-week improvement on the wakefulness test as high certainty (SMD 0.41) and on the Epworth scale as moderate certainty (mean difference -2.25); modafinil-armodafinil probably doubled discontinuation for adverse events (risk ratio 2.01), and solriamfetol was likely more effective. The European Medicines Agency removed the OSA indication in 2011, citing an unfavorable benefit-risk balance. Long-term effects were not well studied.
Bottom line: Modafinil modestly reduces leftover sleepiness in treated sleep apnea, at the cost of more side effects.
excessive sleepiness in shift work disorder
Disease adjunctIn a 3-month double-blind trial, 209 people with chronic shift work sleep disorder took 200 mg modafinil or placebo before each night shift. Nighttime sleep latency improved modestly (1.7 versus 0.3 minutes; P = 0.002), more people improved clinically (74% versus 36%; P < 0.001), lapses of attention fell (a reduction of 2.6 versus an increase of 3.8; P < 0.001), and fewer reported accidents or near accidents driving home (29% versus 54%; P < 0.001). Daytime sleep was not harmed. Despite these gains, people on modafinil still had excessive sleepiness and impaired performance at night. This was a single trial.
Bottom line: Modafinil helps night-shift workers with shift work disorder stay more alert, but it does not make them fully alert.
thinking skills in healthy, rested adults ("smart drug" use, off-label)
Supplement benefitThis is not an approved use. A 2020 meta-analysis of 14 studies (64 effect sizes) in healthy adults who were not sleep-deprived found a small overall effect of modafinil on cognitive tests (SMD 0.12, p = .01), mainly on memory updating (SMD 0.28). The authors concluded that the effects are small, in experiments that do not reflect real-world use, and that the common perception that these drugs are effective cognitive enhancers is not supported by the evidence. A 2015 systematic review found that most simple tests showed better executive function, only half showed better attention or memory, and a few showed worse divergent creative thinking, while more complex tasks showed more consistent gains. The studies were mostly single doses in laboratories; long-term effects in healthy people were not studied.
Bottom line: In healthy, rested adults, modafinil's effect on thinking is small and the "smart drug" reputation outruns the evidence.
How it works
How to take it
What to track
Bottom line: One tablet a day at the time the label sets for your condition; your prescriber sets the dose and checks your other medicines, especially birth control.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
No boxed warning. Serious rash, including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS: in trials in children, rash leading to discontinuation occurred in about 0.8% (13 of 1,585), including a possible case of Stevens-Johnson syndrome; rare serious or life-threatening rashes have been reported in adults and children. Nearly all serious cases began 1 to 5 weeks after starting. The label says to stop modafinil at the first sign of rash unless it is clearly not drug-related.
Angioedema, anaphylaxis and multi-organ allergic reactions: swelling of the face, lips, tongue or throat has been reported after approval, and multi-organ hypersensitivity reactions, including at least one death, have occurred a median of 13 days after starting, often with fever and rash plus heart, liver or blood involvement.
Psychiatric symptoms: mania, delusions, hallucinations, suicidal thoughts and aggression have been reported after approval, some leading to hospitalization; many but not all patients had a prior psychiatric history. The label advises caution with a history of psychosis, depression or mania.
Heart effects: chest pain, palpitations and ECG changes occurred in trial participants with mitral valve prolapse or left ventricular hypertrophy, and one man had a 9-second pause in heartbeat. More patients on modafinil needed new or higher blood pressure medicine (2.4% versus 0.7% on placebo). The label says it is not recommended with left ventricular hypertrophy or stimulant-related mitral valve prolapse syndrome, and to consider more monitoring after a recent heart attack or unstable angina.
Abuse and misuse: modafinil is a Schedule IV controlled substance. In people experienced with drugs of abuse it produced euphoric and psychoactive effects consistent with other scheduled stimulants such as methylphenidate, and the label says patients, especially those with a history of stimulant abuse, should be watched for misuse. Fatal overdoses involving modafinil alone or with other drugs have been reported, and accidental swallowing has occurred in children as young as 11 months.
Persistent sleepiness and driving: wakefulness may not return to normal, and patients may not notice their sleepiness until asked. The label says it is not a replacement for sleep and that patients should not change driving or other risky activities until it is clear their wakefulness permits them.
Who should avoid it
- People with known allergy to modafinil, armodafinil or the tablet's inactive ingredients: contraindicated
- Children and teenagers: not approved for any use in pediatric patients; serious rashes occurred in pediatric trials, and it did not beat placebo in a 6-week trial in children with narcolepsy
- People with left ventricular hypertrophy or mitral valve prolapse syndrome with earlier stimulants (not recommended), and people with known heart disease, severe liver impairment or a history of psychosis, depression, mania or stimulant abuse, who need extra caution
Pregnancy & breastfeeding
Pregnancy: the label (Pregnancy Category C) says there are no adequate and well-controlled studies in pregnant women. Restricted fetal growth and miscarriage have been reported with modafinil and armodafinil, but whether they were caused by the drug is unknown; in rats and rabbits, harm to the developing fetus occurred at exposures similar to human doses. The label says to use it in pregnancy only if the benefit justifies the risk, and a pregnancy registry exists (1-866-404-4106). Hormonal birth control, including pills, shots and implants, may not work during treatment and for one month after stopping, so the label recommends another or an additional method. Breastfeeding: it is not known whether modafinil passes into human milk, and the label advises caution. Talk with your doctor about pregnancy plans and feeding your baby.
Interactions
Modafinil speeds up the liver enzyme CYP3A4, which clears these hormones, so the label says their effectiveness may be reduced during treatment and for one month after stopping. In a study, ethinyl estradiol exposure fell 18%. The label recommends an alternative or additional method of contraception during that time; talk to your prescriber.
By speeding up CYP3A4, modafinil can lower blood levels of these drugs: in one transplant patient, cyclosporine levels fell 50% after a month, and triazolam exposure fell 59% in a study. The label says to monitor cyclosporine levels and consider dose adjustments; your prescriber decides any change.
Modafinil slows the enzyme CYP2C19, so these drugs can build up: armodafinil raised omeprazole exposure by 40%. In people who lack the CYP2D6 enzyme, levels of some antidepressants (tricyclics and SSRIs) may also rise. The label says dose adjustments may be needed; ask your pharmacist to review your list.
Modafinil may affect CYP2C9, the enzyme that clears S-warfarin. A single-dose study found no significant change, but an interaction cannot be ruled out, so the label advises more frequent INR checks when the two are used together.
The label says caution should be used when MAO inhibitors and modafinil are given together. Tell your prescriber if you take any MAO inhibitor.
The Provigil and Nuvigil labels say the use of modafinil or armodafinil in combination with alcohol has not been studied, and advise that it is prudent to avoid alcohol while taking them; the Medication Guide says it is not known how drinking alcohol will affect you on the medicine. This is label advice for an untested combination, not an observed interaction. Tell your prescriber how much you usually drink.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
See all 1 Modafinil interaction →Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is modafinil approved as a smart drug or for focus?⌄
No. Its only approved use is to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea or shift work disorder. In healthy, rested adults, a meta-analysis of 14 studies found only a small effect on cognitive tests, and the authors said the popular view of it as an effective cognitive enhancer is not supported by the evidence.
Is it legal to buy modafinil online without a prescription?⌄
In the US, modafinil is a Schedule IV controlled substance, so it is dispensed only with a prescription.
Does modafinil affect birth control?⌄
Yes. The label says hormonal contraceptives, including pills, shots and implants, may be less effective while taking modafinil and for one month after stopping, and it recommends an alternative or additional method during that time. Talk with your prescriber about which method to use.
Can I take modafinil with my supplements, coffee or alcohol?⌄
There are no studies of modafinil with supplements; the one food or drink interaction listed on this page is alcohol, based on label advice. The label says the combination with alcohol has not been studied and that it is prudent to avoid alcohol. In a study with armodafinil, the label reports no significant effect on the enzyme that clears caffeine. Because modafinil changes the liver enzymes CYP3A4 and CYP2C19, ask your doctor or pharmacist to check your full list, including supplements.
Is modafinil addictive?⌄
It has some abuse potential: it is a Schedule IV controlled substance, and in people experienced with drugs of abuse it produced euphoric effects similar to methylphenidate. In one 9-week trial, no withdrawal symptoms were seen over 14 days after stopping, although sleepiness returned in people with narcolepsy. The label says patients with a history of stimulant abuse should be followed closely.
How does it compare with stimulants like amphetamine?⌄
The label says modafinil's wake-promoting effects are similar to amphetamine and methylphenidate, but its pharmacology is not identical. It is not a direct dopamine agonist, though it blocks dopamine reuptake.
References by claim
excessive daytime sleepiness in narcolepsy
residual sleepiness in obstructive sleep apnea despite CPAP
excessive sleepiness in shift work disorder
Czeisler et al., 2005 · PubMed (2005) link
thinking skills in healthy, rested adults ("smart drug" use, off-label)
Safety
Provigil (modafinil) prescribing information · DailyMed (FDA label) link
Interaction: Alcohol
Nuvigil (armodafinil) prescribing information · DailyMed (FDA label) link
Track Modafinil with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
